Lanzhou Foci Pharmaceutical Co Ltd (002644) - Net Assets

Latest as of September 2025: CN¥1.85 Billion CNY ≈ $270.12 Million USD

Based on the latest financial reports, Lanzhou Foci Pharmaceutical Co Ltd (002644) has net assets worth CN¥1.85 Billion CNY (≈ $270.12 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥2.52 Billion ≈ $369.33 Million USD) and total liabilities (CN¥678.01 Million ≈ $99.21 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check asset resilience ratio of Lanzhou Foci Pharmaceutical Co Ltd to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric Value
Current Net Assets CN¥1.85 Billion
% of Total Assets 73.14%
Annual Growth Rate 14.01%
5-Year Change 14.36%
10-Year Change 47.12%
Growth Volatility 25.82

Lanzhou Foci Pharmaceutical Co Ltd - Net Assets Trend (2007–2024)

This chart illustrates how Lanzhou Foci Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. Also explore 002644 current and non-current assets for the complete picture of this company's asset base.

Annual Net Assets for Lanzhou Foci Pharmaceutical Co Ltd (2007–2024)

The table below shows the annual net assets of Lanzhou Foci Pharmaceutical Co Ltd from 2007 to 2024. For live valuation and market cap data, see 002644 stock market capitalisation.

Year Net Assets Change
2024-12-31 CN¥1.81 Billion
≈ $265.59 Million		 +2.63%
2023-12-31 CN¥1.77 Billion
≈ $258.78 Million		 +1.99%
2022-12-31 CN¥1.73 Billion
≈ $253.73 Million		 +6.54%
2021-12-31 CN¥1.63 Billion
≈ $238.15 Million		 +2.55%
2020-12-31 CN¥1.59 Billion
≈ $232.24 Million		 +5.32%
2019-12-31 CN¥1.51 Billion
≈ $220.51 Million		 +4.62%
2018-12-31 CN¥1.44 Billion
≈ $210.78 Million		 +5.98%
2017-12-31 CN¥1.36 Billion
≈ $198.89 Million		 +5.31%
2016-12-31 CN¥1.29 Billion
≈ $188.85 Million		 +4.61%
2015-12-31 CN¥1.23 Billion
≈ $180.52 Million		 +67.79%
2014-12-31 CN¥735.22 Million
≈ $107.59 Million		 +4.53%
2013-12-31 CN¥703.37 Million
≈ $102.93 Million		 +4.12%
2012-12-31 CN¥675.53 Million
≈ $98.85 Million		 +4.24%
2011-12-31 CN¥648.08 Million
≈ $94.84 Million		 +98.52%
2010-12-31 CN¥326.46 Million
≈ $47.77 Million		 +29.06%
2009-12-31 CN¥252.96 Million
≈ $37.02 Million		 +16.67%
2008-12-31 CN¥216.81 Million
≈ $31.73 Million		 +11.07%
2007-12-31 CN¥195.20 Million
≈ $28.56 Million		 --

Equity Component Analysis

This analysis shows how different components contribute to Lanzhou Foci Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 668.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Retained Earnings CN¥814.87 Million 45.53%
Common Stock CN¥510.66 Million 28.53%
Other Comprehensive Income CN¥164.25 Million 9.18%
Other Components CN¥300.12 Million 16.77%
Total Equity CN¥1.79 Billion 100.00%

Lanzhou Foci Pharmaceutical Co Ltd Competitors by Market Cap

The table below lists competitors of Lanzhou Foci Pharmaceutical Co Ltd ranked by their market capitalization.

Company Market Cap
Voyageurs du Monde SA
PA:ALVDM
 $627.59 Million
Caisse Regionale de Credit Agricole Mutuel de Normandie Seine SC
PA:CCN
 $628.03 Million
RVRC Holding AB
ST:RVRC
 $628.10 Million
Suzhou GYZ Electronic Technology Co. Ltd. A
SHG:688260
 $628.64 Million
Anhui Huamao Textile Co Ltd
SHE:000850
 $626.92 Million
HomeTrust Bancshares, Inc.
NASDAQ:HTB
 $626.83 Million
Betterware de México, S.A.P.I. de C.V.
NYSE:BWMX
 $626.82 Million
BizConf Telecom Co Ltd
SHE:300578
 $626.68 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Lanzhou Foci Pharmaceutical Co Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 1,745,370,807 to 1,789,888,294, a change of 44,517,487 (2.6%).
  • Net income of 60,069,813 contributed positively to equity growth.
  • Dividend payments of 15,955,346 reduced retained earnings.
  • Other comprehensive income increased equity by 163,035,357.
  • Other factors decreased equity by 162,632,337.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income CN¥60.07 Million +3.36%
Dividends Paid CN¥15.96 Million -0.89%
Other Comprehensive Income CN¥163.04 Million +9.11%
Other Changes CN¥-162.63 Million -9.09%
Total Change CN¥- 2.55%

Book Value vs Market Value Analysis

This analysis compares Lanzhou Foci Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 2.39x
  • The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
  • The price-to-book ratio has decreased from 14.50x to 2.39x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2007-12-31 CN¥0.58 CN¥8.39 x
2008-12-31 CN¥0.66 CN¥8.39 x
2009-12-31 CN¥0.76 CN¥8.39 x
2010-12-31 CN¥0.98 CN¥8.39 x
2011-12-31 CN¥1.94 CN¥8.39 x
2012-12-31 CN¥1.52 CN¥8.39 x
2013-12-31 CN¥1.58 CN¥8.39 x
2014-12-31 CN¥2.05 CN¥8.39 x
2015-12-31 CN¥2.61 CN¥8.39 x
2016-12-31 CN¥2.53 CN¥8.39 x
2017-12-31 CN¥2.66 CN¥8.39 x
2018-12-31 CN¥2.82 CN¥8.39 x
2019-12-31 CN¥2.95 CN¥8.39 x
2020-12-31 CN¥3.10 CN¥8.39 x
2021-12-31 CN¥3.16 CN¥8.39 x
2022-12-31 CN¥3.36 CN¥8.39 x
2023-12-31 CN¥3.42 CN¥8.39 x
2024-12-31 CN¥3.50 CN¥8.39 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Lanzhou Foci Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 3.36%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 6.13%
  • • Asset Turnover: 0.40x
  • • Equity Multiplier: 1.38x
  • Recent ROE (3.36%) is below the historical average (6.67%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2007 11.94% 13.13% 0.49x 1.84x CN¥3.79 Million
2008 9.97% 9.87% 0.55x 1.85x CN¥-72.05K
2009 14.29% 15.57% 0.55x 1.67x CN¥10.85 Million
2010 15.70% 19.53% 0.58x 1.40x CN¥18.60 Million
2011 4.95% 11.82% 0.33x 1.28x CN¥-32.75 Million
2012 4.49% 11.40% 0.32x 1.22x CN¥-37.20 Million
2013 4.35% 10.50% 0.32x 1.28x CN¥-39.74 Million
2014 4.71% 8.68% 0.38x 1.42x CN¥-38.87 Million
2015 3.48% 13.11% 0.24x 1.10x CN¥-80.42 Million
2016 4.72% 16.77% 0.18x 1.58x CN¥-68.13 Million
2017 5.45% 14.78% 0.21x 1.73x CN¥-61.82 Million
2018 5.06% 13.39% 0.22x 1.75x CN¥-71.12 Million
2019 4.73% 11.31% 0.26x 1.60x CN¥-79.38 Million
2020 6.83% 16.17% 0.28x 1.51x CN¥-50.19 Million
2021 5.78% 11.41% 0.35x 1.46x CN¥-68.20 Million
2022 6.33% 10.66% 0.39x 1.51x CN¥-62.88 Million
2023 3.85% 5.78% 0.46x 1.45x CN¥-107.35 Million
2024 3.36% 6.13% 0.40x 1.38x CN¥-118.92 Million

Industry Comparison

This section compares Lanzhou Foci Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

  • Industry: Drug Manufacturers - Specialty & Generic
  • Average net assets among peers: $1,347,197,696
  • Average return on equity (ROE) among peers: 4.46%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Lanzhou Foci Pharmaceutical Co Ltd (002644) CN¥1.85 Billion 11.94% 0.37x $626.94 Million
Shenzhen Neptunus Bioengineering Co Ltd (000078) $2.84 Billion -41.97% 9.13x $1.22 Billion
Anhui Fengyuan Pharmaceutical Co Ltd (000153) $638.89 Million 0.88% 0.70x $438.59 Million
Shan Dong Dong-E E-Jiao Co Ltd (000423) $1.05 Billion 10.46% 0.19x $5.18 Billion
Livzon Pharmaceutical Group Inc (000513) $1.07 Billion 3.83% 0.46x $2.81 Billion
Wedge Industrial Co Ltd (000534) $1.29 Billion 11.69% 1.47x $2.95 Billion
Yunnan Baiyao Group Co Ltd (000538) $35.11 Million 18.13% 0.80x $13.85 Billion
Hainan Haiyao Co Ltd (000566) $5.08 Billion 1.71% 1.08x $949.23 Million
Tus Pharmaceutical Group Co Ltd (000590) $141.91 Million 11.01% 0.32x $391.07 Million
Northeast Pharmaceutical Group Co Ltd (000597) $994.58 Million 2.01% 2.11x $1.03 Billion
Jilin Aodong Pharmaceutical Group Co Ltd (000623) $332.48 Million 26.89% 0.68x $3.30 Billion

About Lanzhou Foci Pharmaceutical Co Ltd

SHE:002644 China Drug Manufacturers - Specialty & Generic
Market Cap
$626.94 Million
CN¥4.28 Billion CNY
Market Cap Rank
#11375 Global
#3431 in China
Share Price
CN¥8.39
Change (1 day)
+2.07%
52-Week Range
CN¥7.79 - CN¥11.76
All Time High
CN¥18.02
Categories
Companies in China Drug Manufacturers - Specialty & Generic
About

LanZhou Foci Pharmaceutical Co.,Ltd., research and development, production, and sales of traditional chinese medicines and health products in China. The company offers its products in various dosage forms, including pills, tablets, granules, capsules, and gelatin under the MingShan, BaoShu, BaoLu, and Foci brands. It also engages in planting and selling of Chinese medicinal materials; processing … Read more